Company: WHWK
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001628280-25-020311
Chunk: 32

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 32
---
 |     | 2024 |     |            | 403,936 |     |        |       — |     |                     |  57,600 |     |               |   194,543 |     |              |      — |     |              |   973,995 |     |           | 1,630,074 |
| Former Chief Medical Officer          |     | 2023 |     |            | 521,475 |     |        |       — |     |                     |       — |     |               |   858,234 |     |              | 44,322 |     |              |    51,654 |     |           | 1,475,685 |

(1) These amounts represent payment of (i) a $100,000 cash sign-on bonus paid to Dr. Lennon in connection with his commencement of employment with us and (ii) a $43,000 per calendar quarter cash bonus (pro-rated for the actual number of days in each quarterly period Mr. Giacobello served as our Interim Chief Executive Officer and President).

(2) These amount reported in the Stock Awards column represents the grant date fair value of restricted stock units granted to the named executive officer as of the grant date as computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, not including any estimates of forfeitures. The assumptions used in calculating the grant date fair value of the restricted stock units reported in the Stock Awards column are set f orth in Note 9 to our financial statements included in our Annual Report on Form 10-K for the year ended December 31 , 2024.

(3) The amounts reported in the Option Awards column represent the grant date fair value of the stock options granted to the named executive officers as of the grant date as computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, not including any estimates of forfeitures. The assumptions used in calculating the grant date fair value of the stock options reported in the Option Awards column are set f orth in Note 9 to our financial statements included in our Annual Report on Form 10-K for the year ended December 31 , 2024. Note that the amounts reported in this column reflect the accounting cost for these stock options, and do not correspond to the actual economic value that may be received by the named executive officers from the options.

(4) Amount represents cash bonus earned for performance in 2023 based upon achievement of corporate performance goals. No cash bonus was